DK0994875T3 - 3-Pyridyl-1-azabicycloalkanderivater til forhindring og behandling af afvigelser i centralnervesystemet - Google Patents

3-Pyridyl-1-azabicycloalkanderivater til forhindring og behandling af afvigelser i centralnervesystemet

Info

Publication number
DK0994875T3
DK0994875T3 DK98918598T DK98918598T DK0994875T3 DK 0994875 T3 DK0994875 T3 DK 0994875T3 DK 98918598 T DK98918598 T DK 98918598T DK 98918598 T DK98918598 T DK 98918598T DK 0994875 T3 DK0994875 T3 DK 0994875T3
Authority
DK
Denmark
Prior art keywords
pyridyl
aza
bicyclo
nervous system
central nervous
Prior art date
Application number
DK98918598T
Other languages
English (en)
Inventor
William Scott Caldwell
Merouane Bencherif
Gary Maurice Dull
Peter Anthony Crooks
Patrick Michael Lippiello
Balwinder Singh Bhatti
Niranjan Madhukar Deo
Alain Ravard
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/885,397 external-priority patent/US6525065B1/en
Priority claimed from US08/885,768 external-priority patent/US6624173B1/en
Application filed by Targacept Inc filed Critical Targacept Inc
Application granted granted Critical
Publication of DK0994875T3 publication Critical patent/DK0994875T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98918598T 1997-06-30 1998-04-22 3-Pyridyl-1-azabicycloalkanderivater til forhindring og behandling af afvigelser i centralnervesystemet DK0994875T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/885,397 US6525065B1 (en) 1997-06-30 1997-06-30 Pharmaceutical compositions and methods for effecting dopamine release
US08/885,768 US6624173B1 (en) 1997-06-30 1997-06-30 Pharmaceutical compositions for treating and/or preventing CNS disorders

Publications (1)

Publication Number Publication Date
DK0994875T3 true DK0994875T3 (da) 2004-06-21

Family

ID=27128761

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98918598T DK0994875T3 (da) 1997-06-30 1998-04-22 3-Pyridyl-1-azabicycloalkanderivater til forhindring og behandling af afvigelser i centralnervesystemet

Country Status (10)

Country Link
EP (1) EP0994875B1 (da)
JP (1) JP2002511090A (da)
AT (1) ATE261443T1 (da)
AU (1) AU7149798A (da)
CA (1) CA2294990C (da)
DE (1) DE69822300T2 (da)
DK (1) DK0994875T3 (da)
ES (1) ES2214707T3 (da)
PT (1) PT994875E (da)
WO (1) WO1999000385A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
AU780492B2 (en) * 1999-11-01 2005-03-24 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6890935B2 (en) 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
AU8656101A (en) * 2000-08-21 2002-03-04 Univ Georgetown 2-3-disubstituted quinuclidines as modulators of monoamine transporters and therapeutic and diagnostic methods based thereon
WO2002024681A2 (en) 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
JP4923630B2 (ja) * 2006-03-02 2012-04-25 宇部興産株式会社 ４−置換テトラヒドロピランの製造方法
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5413441B2 (ja) * 2011-12-09 2014-02-12 宇部興産株式会社 ４−置換テトラヒドロピランの製造方法
CN104311514B (zh) * 2014-10-14 2016-06-22 安徽扬子化工有限公司 3-羟甲基四氢呋喃酯的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03135978A (ja) * 1989-08-08 1991-06-10 Merck Sharp & Dohme Ltd 置換ピリジン、その製法、処方並びに痴呆症における使用法
US5242935A (en) * 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
WO1995003306A1 (en) * 1993-07-22 1995-02-02 E.I. Du Pont De Nemours And Company Arthropodicidal azacyclic heterocycles
US5510355A (en) * 1994-09-06 1996-04-23 Bencherif; Merouane Depolarizing skeletal muscle relaxants
AU5383196A (en) * 1995-05-17 1996-11-29 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders

Also Published As

Publication number Publication date
ES2214707T3 (es) 2004-09-16
EP0994875B1 (en) 2004-03-10
DE69822300T2 (de) 2005-03-10
JP2002511090A (ja) 2002-04-09
DE69822300D1 (de) 2004-04-15
WO1999000385A1 (en) 1999-01-07
CA2294990C (en) 2007-03-06
EP0994875A1 (en) 2000-04-26
AU7149798A (en) 1999-01-19
ATE261443T1 (de) 2004-03-15
PT994875E (pt) 2004-06-30
CA2294990A1 (en) 1999-01-07

Similar Documents

Publication Publication Date Title
Maelicke et al. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
WO2004108668A3 (en) Alpha-7 neuronal nicotinic receptor ligands: compositions and methods of use
Maelicke et al. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer’s disease
PL1678172T3 (pl) Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego
DK0994875T3 (da) 3-Pyridyl-1-azabicycloalkanderivater til forhindring og behandling af afvigelser i centralnervesystemet
MXPA02001306A (es) Composiciones farmaceuticas para el tratamiento de enfermedades del sistema nervioso central y otras enfermedades.
PL398445A1 (pl) Kompozycje farmaceutyczne zawierające dekstrometorfan i chininę do leczenia zaburzeń neurologicznych
NO20041166L (no) Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament
NO20100496L (no) Derivater av venlafaksin og anvendelse av samme
PH31335A (en) Naphthalamides as central nervous system agent.
EP0348360A3 (en) Pharmacological use of uridine in the treatment of nervous disorders
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
WO2007058805A3 (en) Compositions and methods for treating cns disorders
IL192287A0 (en) Pharmaceutical compositions and methods for use
IL113436A0 (en) Neurotransmitter release enhancers
DE69224448D1 (de) Imidazol-Verbindungen, Verfahren zu ihrer Herstellung und ihre Anwendung
AU4038000A (en) 4-substituted quinoline derivatives as gaba receptor ligands
HU9502848D0 (en) Imidazoloquinoxalinone derivatives as eaa antagonists
NZ515613A (en) Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands
AU2002243310A1 (en) Isoindolyl and isoquinolinyl aroyl pyrrole compounds for the treatment of central nervous system disorders